• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-world analysis of the safety/tolerability of gilteritinib in combination with mold-active azole prophylaxis.

作者信息

King Amber C, Derkach Andriy, Weis Taylor M, Stump Sarah E, Ciervo Jenna R, Ranaghan Coleen P, Stein Eytan S

机构信息

Department of Pharmacy, Clinical Programs, Memorial Sloan Kettering Cancer, New York, NY, USA.

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Leuk Res. 2022 Nov;122:106929. doi: 10.1016/j.leukres.2022.106929. Epub 2022 Sep 6.

DOI:10.1016/j.leukres.2022.106929
PMID:36244178
Abstract
摘要

相似文献

1
Real-world analysis of the safety/tolerability of gilteritinib in combination with mold-active azole prophylaxis.
Leuk Res. 2022 Nov;122:106929. doi: 10.1016/j.leukres.2022.106929. Epub 2022 Sep 6.
2
Gilteritinib induces differentiation in relapsed and refractory -mutated acute myeloid leukemia.吉特替尼诱导复发/难治性突变型急性髓系白血病的分化。
Blood Adv. 2019 May 28;3(10):1581-1585. doi: 10.1182/bloodadvances.2018029496.
3
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.吉瑞替尼对复发或难治性急性髓系白血病中FLT3的选择性抑制作用：一项多中心、首例人体、开放标签的1-2期研究。
Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20.
4
Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML.吉特替尼联合阿扎胞苷组合在新诊断的 FLT3 突变 AML 中显示出前景。
Oncologist. 2021 Feb;26 Suppl 1(Suppl 1):S10. doi: 10.1002/onco.13652. Epub 2020 Dec 24.
5
A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer.吉瑞替尼与促黄体生成素释放激素（LH-RH）激动剂联合治疗Fms相关酪氨酸激酶3受体突变阳性急性髓系白血病合并前列腺癌骨髓转移的病例报告
Ann Hematol. 2022 Feb;101(2):457-458. doi: 10.1007/s00277-021-04516-w. Epub 2021 Apr 12.
6
Gilteritinib Changes AML Landscape.吉列替尼改变急性髓系白血病格局。
Oncology (Williston Park). 2019 Aug 23;33(8):683729.
7
Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.吉瑞替尼：一种用于治疗复发或难治性急性髓系白血病患者的类FMS样酪氨酸激酶3/AXL酪氨酸激酶抑制剂。
J Oncol Pharm Pract. 2020 Jul;26(5):1200-1212. doi: 10.1177/1078155220918006. Epub 2020 Apr 26.
8
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a mutation.吉特替尼用于治疗携带 突变的复发或难治性急性髓系白血病。
Future Oncol. 2021 Jan;17(2):215-227. doi: 10.2217/fon-2020-0700. Epub 2020 Sep 25.
9
Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial.吉瑞替尼与挽救性化疗治疗FLT3突变型急性髓系白血病的比较：基于ADMIRAL试验二次分析的临床结局所需治疗人数
Leuk Lymphoma. 2022 Mar;63(3):762-764. doi: 10.1080/10428194.2021.2001467. Epub 2021 Nov 8.
10
Successful treatment with gilteritinib for initially FMS-like tyrosine kinase 3 gene internal tandem duplications-positive elderly refractory acute myeloid leukemia that changed into FMS-like tyrosine kinase 3 gene tyrosine kinase domain-positive after cord blood transplantation.吉瑞替尼成功治疗初诊为FMS样酪氨酸激酶3基因内部串联重复阳性的老年难治性急性髓系白血病，该患者在脐血移植后转变为FMS样酪氨酸激酶3基因酪氨酸激酶结构域阳性。
Geriatr Gerontol Int. 2019 Oct;19(10):1063-1064. doi: 10.1111/ggi.13772.

引用本文的文献

1
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.新型药物联合治疗急性髓系白血病：异质性疾病治疗的新视角。
Br J Haematol. 2024 Jul;205(1):30-47. doi: 10.1111/bjh.19519. Epub 2024 May 9.
2
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data.使用吉列替尼后出现的严重胃肠道毒性：病例系列及上市后监测数据分析
Healthcare (Basel). 2023 May 18;11(10):1479. doi: 10.3390/healthcare11101479.